Cronos Group Accounts Receivables 2011-2026 | CRON

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Cronos Group

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
34.1 M	15.5 M	14 M	23.1 M	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
34.1 M	14 M	21.7 M

Quarterly Accounts Receivables Cronos Group

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
33 M	27.1 M	26.6 M	18.7 M	20.5 M	16.2 M	15.3 M	15.7 M	12.5 M	14.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
33 M	12.5 M	20.1 M

Accounts Receivables of other stocks in the Drug manufacturers industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Endo International plc ENDP	387 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	2.42 M	-	-	$ 36.6 M	USA
Cumberland Pharmaceuticals CPIX	16.9 M	$ 5.64	-3.42 %	$ 83.8 M	USA
AcelRx Pharmaceuticals ACRX	309 K	-	7.5 %	$ 6.35 M	USA
DURECT Corporation DRRX	453 K	-	-	$ 50.1 M	USA
Adamis Pharmaceuticals Corporation ADMP	1.05 M	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	68.8 M	-	-	$ 754 M	USA
Agile Therapeutics AGRX	3.39 M	-	10.11 %	$ 58.2 M	USA
Alimera Sciences ALIM	34.5 M	-	-	$ 142 M	USA
Athenex ATNX	27.9 M	-	-23.39 %	$ 1.76 M	USA
Harrow Health HROW	111 M	$ 33.79	-2.59 %	$ 1.24 B	USA
Avadel Pharmaceuticals plc AVDL	34.1 M	-	-	$ 2.06 B	France
Catalent CTLT	921 M	-	-	$ 11.5 B	USA
Eagle Pharmaceuticals EGRX	72.4 M	-	-39.89 %	$ 27.7 M	USA
Organogenesis Holdings ORGO	217 M	$ 2.46	-0.81 %	$ 312 M	USA
Canopy Growth Corporation CGC	47.5 M	$ 1.01	-2.4 %	$ 109 M	Canada
Pacira BioSciences PCRX	113 M	$ 22.91	1.04 %	$ 1.06 B	USA
Sonoma Pharmaceuticals SNOA	2.23 M	$ 1.15	-4.96 %	$ 1.43 M	USA
Jupiter Wellness JUPW	90.1 K	-	-	$ 33.6 M	USA
Tilray TLRY	86.2 M	$ 4.91	-5.49 %	$ 3.03 B	Canada
Lannett Company LCI	56.2 M	-	1.15 %	$ 7.11 M	USA
Evolus EOLS	54.7 M	$ 6.41	-2.88 %	$ 413 M	USA
Emergent BioSolutions EBS	84.2 M	$ 8.09	-4.03 %	$ 433 M	USA
cbdMD YCBD	786 K	$ 0.74	-1.61 %	$ 2.98 M	USA
Veru VERU	3.96 M	$ 3.63	-14.18 %	$ 53.2 M	USA
Neoleukin Therapeutics NLTX	65.4 K	-	-	$ 193 M	Canada
Assertio Holdings ASRT	120 M	$ 23.45	-	$ 150 M	USA
ProPhase Labs PRPH	1.54 M	-	-	$ 5.07 M	USA
Radius Health RDUS	23.4 M	-	-	$ 1.42 B	USA
Bausch Health Companies BHC	2.35 B	$ 5.33	1.53 %	$ 1.98 B	Canada
PetIQ PETQ	143 M	-	1.64 %	$ 400 M	USA
Relmada Therapeutics RLMD	512 K	$ 5.87	-7.05 %	$ 232 M	USA
Recro Pharma REPH	16.6 M	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	26.4 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	2.1 M	$ 4.72	-3.28 %	$ 236 M	USA
PLx Pharma PLXP	634 K	-	-27.8 %	$ 2.56 M	USA
Viatris VTRS	2.58 B	$ 16.0	0.63 %	$ 18.6 B	USA
Zomedica Corp. ZOM	3.01 M	-	-0.21 %	$ 98 M	USA
Rockwell Medical RMTI	8.14 M	$ 0.65	-6.27 %	$ 23.4 M	USA
China Pharma Holdings CPHI	241 K	$ 0.83	0.97 %	$ 3.56 M	China
TherapeuticsMD TXMD	32.4 M	$ 1.95	-2.5 %	$ 22.6 M	USA